UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
VTVT(NASDAQ:VTVT) HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
VTVTHIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041.
vTv Therapeutics Appoints Michael Tung As EVP And CFO, Effective Immediately
VTVTvTv Therapeutics Q1 EPS $(0.77) Beats $(0.92) Estimate
VTVTvTv Therapeutics Resumes Screening In Phase 3 CATT1 Study Evaluating Cadisegliatin as Adjunctive Therapy for Type 1 Diabetes
VTVTHC Wainwright & Co. Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $36
VTVTvTv Therapeutics Q4 2024 GAAP EPS $(0.55) Beats $(0.87) Estimate
VTVTFDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
VTVTvTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.
vTv Therapeutics Says FDA Has Lifted Clinical Hold On Cadisegliatin Program For Diabetes, CATT1 Phase 3 Trial Expected To Resume Following Submission Of Protocol Amendment Shortening Overall Duration Of Trial From 12 To 6 Months
VTVTCantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By vtv Therapeutics, Which Cantex Licensed Worldwide R
VTVT